• Publications
  • Influence
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
TLDR
The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation, and AMG 510 is a potential new drug candidate.
Biosimilars 101: considerations for U.S. oncologists in clinical practice
TLDR
Broad understanding of these issues is critical for oncologists preparing for their use in clinical practice and potential cost savings should be evaluated in the context of differences in manufacturers' patient‐assistance programs, copayments, and institutional costs.
Hot flashes: a review of pathophysiology and treatment modalities.
TLDR
The purpose of this paper is to assess the current options for the management of hot flashes, examining key endpoints from recent clinical trials and reviewing future directions.
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
TLDR
Inhibition of mTOR results in clinical benefit and disease response in patients with trastuzumab-resistant HER2-overexpressing MBC, and patients with PTEN loss demonstrated decreased overall survival.
Depressive symptoms and health-related quality of life in breast cancer survivors.
TLDR
Depression is a significant health concern for breast cancer survivors and is associated with lower HRQOL and the need to monitor women with breast cancer for depression and provide resources for treating depression during the survival period is suggested.
A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
TLDR
Low-dose methylphenidate did not improve cancer-related fatigue and patients takingmethylphenidate had better cognition and were able to work more hours.
...
...